The health policy program will continue to showcase the strengths of the Murphy Institute by harnessing the expertise of the Health Policy Working Group, with the goal of producing interdisciplinary research that addresses critical healthcare policy issues. The working group has already established a network of professionals from Tulane’s uptown and downtown campuses who are beginning to collaborate on research projects.
Mary Olson is an Associate Professor of Economics at Tulane and leader of the Health Policy Working Group. Professor Olson’s teaching and research interests include health economics, the political economy of health policy, regulation, and the study of bureaucracy. She is an expert on Food and Drug Administration (FDA) regulation. Her current research interests include studying the regulatory and firm-specific determinants of drug safety.
Nina Yin is the post-doctoral fellow for the Health Policy Program. She obtained her PhD degree from Toulouse School of Economics, France in 2013. Before that, she obtained an M.A. from the China Center for Economic Research, Peking University. Her research interests involve health economics, empirical industrial organization and the economics of innovation and intellectual property. Her current work focuses on policy issues related to the patent and data exclusivities granted to the incremental innovation in the pharmaceutical industry. Policy makers wonder whether it’s beneficial to grant patent and data exclusivities to the incremental innovations of the existing drugs. On the one hand, it encourages investments in R&D for drug improvements, which is better tailored to patients’ needs and improves drug safety and efficacy; on the other hand, the market exclusivity permits brand drugs to dominate the market with monopoly pricing, which brings about consumer surplus loss. Her work measures these two blocks of value and provides interesting policy implications.